Table 5.
Currently available follow-on biologic or biosimilar U-100 insulins.
| Product Name | Manufacturer | Reference Product | Molecule | Approvals |
|---|---|---|---|---|
| Follow-on biologic/biosimilar insulins | ||||
| Basaglar®, Abasaglar® | Eli Lilly | Lantus® | Insulin glargine | FDA 2015; EMU 2014 |
| Basalin® | Gan & Lee | Lantus® | Insulin glargine | China 2005 |
| Semglee® | Biocon/Mylan | Lantus® | Insulin glargine | FDA under review; EU, Australia 2018 |
| Admelog® | Sanofi | Humalog® | Insulin lispro | FDA 2017 |